TD Cowen analyst Joshua Jennings lowered the firm’s price target on Edwards Lifesciences to $80 from $100 and keeps an Outperform rating on the shares. The firm said the company delivered third-quarter results that matched Street expectations on both revenue and adjusted EPS, but the TAVR revenue result came in just beneath expectations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences price target lowered to $84 from $100 at JPMorgan
- Edwards Lifesciences price target lowered to $75 from $91 at Baird
- Edwards Lifesciences price target lowered to $85 from $90 at Mizuho
- Edwards Lifesciences price target lowered to $75 from $88 at Wells Fargo
- Edwards Lifesciences price target lowered to $85 from $94 at Citi